Brian Thomas, Metagenomi CEO
On the road to human studies, next-gen gene editing contender Metagenomi hauls in an extra $100M
One of the up-and-comers in the gene editing field is banking an extra $100 million and boosting their B round to a hefty $275 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
